Enzymatica AB (publ) (STO:ENZY)
1.685
-0.005 (-0.30%)
Sep 25, 2026, 9:09 AM CET
Enzymatica AB Earnings Call Transcripts
Fiscal Year 2025
-
Recent independent studies confirm ColdZyme significantly reduces the duration and severity of upper respiratory infections by lowering viral load, as shown in both athlete-based and cell culture models. The product demonstrated strong efficacy and safety, with results expected to apply to the general population.